savene
clinigen healthcare b.v. - dexrazoxane hydrochloride - ekstravaziranje dijagnostičkih i terapeutskih materijala - svi ostali terapeutski proizvodi - savene je indiciran za liječenje antraciklin ekstravazacija.
medeson, 1 mg/ml, otopina za injekciju za pse i mačke
industrial veterinaria, s.a., esmeralda 19, e-08950 esplugues de llobregat (barcelona), Španjolska - medetomidin hidroklorid - otopina za injekciju - hhipnotici i sedativi - pasa, mačaka
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptici sredstva, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
medeson 1 mg/ml
industrial veterinaria, s.a., esmeralda 19, e-08950 esplugues de llobregat (barcelona), Španjolska - medetomidin hidroklorid - otopina za injekciju za pse i mačke - pasa, mačaka
sitagliptin accord
accord healthcare s.l.u. - sitagliptin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multipli mijelom - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
pd pribor-kateter adaptor luer-lock s closure cap, stay safe kateter extension luer-lock 32 cm, stay safe disinfection cap i sta
fresenius medical care hrvatska d.o.o., zagreb - pribor za peritonejsku dijalizu
prineo skin closure sistem
johnson & johnson s.e. d.o.o., zagreb - sustav za zatvaranje kože za površinsku primjenu
perclose proglide suture -mediated closure system
mark medical d.o.o. budmanijeva 5 10000 zagreb -
venaseal closure system model: sp-101 vs-403
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - medicinska sredstva za jednokratnu upotrebu